| Detailed information |
|---|
| CancerLivER ID | 2088 |
| Biomarker | Aspartate aminotransferase to white blood cell count ratio (AWR) |
| Biomarker Name/Symbol (given in Publication) | Aspartate aminotransferase to white blood cell count ratio (AWR) |
| Biomolecule | Others |
| Subject | Human |
| Degree of Validity | Prognostic biomarker in HCC ; but not validated on independent dataset |
| Experimental Condition | HCC patients with AWR >5.2 v/s HCC patients with AWR <5.2; predict survival of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | AWR > 5.2 was an adverse predictor of DFS and OS in HCC after hepatectomy |
| Level of significance | p < 0.01 |
| Source | Blood |
| PMID | 27057915 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 396 HCC patients who underwent hepatic resection at the Affiliated Hospital of Guilin Medical University (Guilin, China) from March 1997 to May 2008. |
| Sensitivity | 67.9 % |
| Specificity | 66.8 % |
| Accuracy | NA |
| AUC | 0.668 |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |